Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma
- Sponsor
- University of Turku
- Study ID
- NCT00308607
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Bevacizumab (Avastin) — DRUG
- dacarbazine — DRUG
- interferon-alfa-2a (Roferon-A) — DRUG
Study Details
The purpose of this study is to determine whether combination therapy with bevacizumab (Avastin), dacarbazine and interferon-alfa-2a (Roferon-A) is effective in patients with locally advancing or metastatic melanoma.
Key Dates
- First listed
- Mar 29, 2006
- Start date
- Aug 31, 2005
- Status verified
- Apr 2009
- Primary completion
- Dec 31, 2008
- Completion
- Apr 30, 2009
Study Design
- Enrollment
- 27 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
Response rate according to RECIST criteria
Related Studies
- Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic MelanomaPHASE2 · Recruiting · Abramson Cancer Center at Penn Medicine · Lancaster, Pennsylvania
- Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsPHASE1 · Recruiting · Anusha Kalbasi · Duarte, California
- A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesPHASE2 · Recruiting · SWOG Cancer Research Network · Birmingham, Alabama
- Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME TrialRecruiting · M.D. Anderson Cancer Center · Houston, Texas